Saturday, 10 October 2026European Markets

VERIMATRIX Stock Went Down By Over 22% In The Last 10 Sessions

Loading stream...

(vianews) - shares of verimatrix (cac 40: vmx.pa) dropped by a staggering 22.5% in 10 sessions from €0.8 to €0.62 at 19:07 est on wednesday, after two consecutive sessions in a row of gains. cac 40 is jumping 0.26% to €7,131.12, after two sequential sessions in a row of gains.

about verimatrix

verimatrix société anonyme provides security solutions that protect digital content, applications, and devices worldwide. the company offers security solutions for various markets, including automotive, sports, financial services, healthcare, internet of things, live sports, media and entertainment, and tv, as well as for content owners. the company was formerly known as inside secure s.a. and changed its name to verimatrix société anonyme in july 2017. verimatrix société anonyme was founded in 1995 and is based in meyreuil, france.

earnings per share

as for profitability, verimatrix has a trailing twelve months eps of €-0.021.

volume

today's last reported volume for verimatrix is 88339 which is 37.45% below its average volume of 94557.

more news about verimatrix (vmx.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com